Page last updated: 2024-08-23

staurosporine and Nausea

staurosporine has been researched along with Nausea in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	2 (66.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Coleman, M; Fechter, L; Galinsky, I	1
Bolstad, B; Dahlseng Håkonsen, G; Dalhus, M; Gisselbrecht, C; Hennik, P; Herberts, C; Kaasboll, T; Meulendijks, D; Pignatti, F; Salmonson, T; Tzogani, K; Verheijen, R; Wangen, T; Yu, Y	1
Arbuck, SG; Bauer, KS; Figg, WD; Fuse, E; Headlee, D; Jaken, S; Jing , X; Kuwabara, T; Lahusen, T; Lush, RM; Messmann, R; Murgo, A; Roberge, M; Sausville, EA; Senderowicz, AM	1

Reviews

1 review(s) available for staurosporine and Nausea

Article	Year
European Medicines Agency review of midostaurin (Rydapt) for the treatment of adult patients with acute myeloid leukaemia and systemic mastocytosis. ESMO open, 2019, Volume: 4, Issue:6 Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Approval; Edema; European Union; Fatigue; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Mastocytosis, Systemic; Middle Aged; Nausea; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Risk Assessment; Staurosporine; Vomiting	2019

Article

Year

European Medicines Agency review of midostaurin (Rydapt) for the treatment of adult patients with acute myeloid leukaemia and systemic mastocytosis.

ESMO open, 2019, Volume: 4, Issue:6

Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Approval; Edema; European Union; Fatigue; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Mastocytosis, Systemic; Middle Aged; Nausea; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Risk Assessment; Staurosporine; Vomiting

2019

Trials

1 trial(s) available for staurosporine and Nausea

Article	Year
Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8 Topics: Adult; Aged; Alkaloids; Antineoplastic Agents; DNA Damage; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Hyperglycemia; Hypotension; Infusions, Intravenous; Lymphoma, Large B-Cell, Diffuse; Male; Melanoma; Middle Aged; Nausea; Neoplasms; Skin Neoplasms; Staurosporine; Vomiting	2001

Article

Year

Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

Topics: Adult; Aged; Alkaloids; Antineoplastic Agents; DNA Damage; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Hyperglycemia; Hypotension; Infusions, Intravenous; Lymphoma, Large B-Cell, Diffuse; Male; Melanoma; Middle Aged; Nausea; Neoplasms; Skin Neoplasms; Staurosporine; Vomiting

2001

Other Studies

1 other study(ies) available for staurosporine and Nausea

Article	Year
Midostaurin: Nursing Perspectives on Managing Treatment and Adverse Events in Patients With FLT3 Mutation-Positive Acute Myeloid Leukemia and Advanced Systemic Mastocytosis. Clinical journal of oncology nursing, 2019, 12-01, Volume: 23, Issue:6 Topics: Antineoplastic Agents; Humans; Leukemia, Myeloid, Acute; Mastocytosis, Systemic; Nausea; Staurosporine; United States; Vomiting	2019